AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2670633
Drug: Erythromycin ethylsuccinate
RxNorm normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin ethylsuccinate (2 g/day)
Trial: 773506
Drug: Amitriptyline (75‐225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (75‐225 mg/day)
Trial: 773506
Drug: Flupenthixol (1‐5‐4‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupenthixol (1‐5‐4‐5 mg/day)
Trial: 19502645
Drug: Insulin-sensitization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-sensitization therapy
Trial: 19502645
Drug: Insulin-provision therapy
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin-provision therapy
Trial: 22220945
Drug: 1.0 μg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 μg/kg DMT
Trial: 17378781
Drug: Pre‐emptive stellate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre‐emptive stellate ganglion block (SGB) using 10 ml of ropivacaine
Trial: 16323385
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation combined with AChE‐I (rivastigmine) treatment
Trial: 12006327
Drug: Alendronate 20
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 20 mg daily
Trial: 12006327
Drug: Ibandronate 5
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate 5 mg daily
Trial: 10049274
Drug: Abacavir (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (100, 300, 600, 900, and 1,200 mg)
Trial: 10049274
Drug: Abacavir (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (300 mg)
Trial: 10049274
Drug: Abacavir (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (various doses)
Trial: 10049274
Drug: Abacavir (caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abacavir (caplet formulation)
Trial: 1971645
Drug: Ceftazidime and
RxNorm normalized name: Ceftazidime and Avibactam for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime and Gentamicin (C + G)
Trial: 1971645
Drug: Ceftazidime, Gentamicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime, Gentamicin, and Teicoplanin (C + G + T)
Trial: 24634622
Drug: Mandibular advancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mandibular advancement splint (MAS) therapy for 6 months
Trial: 21952002
Drug: Exercise Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise Group (EG) - 30 minutes of brisk walking daily for 3 weeks
Trial: 17241844
Drug: PSS placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSS placebo gel
Trial: 15962898
Drug: ORS/WHO standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS/WHO standard treatment
Trial: 15962898
Drug: ORS/plantain solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS/plantain solution (50 g of precooked plantain flour instead of glucose)
Trial: 15962898
Drug: ORS/plantain solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS/plantain solution
Trial: 9796961
Drug: Cremophor 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor 30 ml/m2
Trial: 9796961
Drug: Cremophor 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor 45 ml/m2 with 35 mg/m2 doxorubicin
Trial: 9796961
Drug: Cremophor 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor 60 ml/m2
Trial: 9796961
Drug: Cremophor 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cremophor 45 ml/m2 and 60 ml/m2
Trial: 7899064
Drug: Combined concurrent
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined concurrent bronchial artery infusion (BAI) of CDDP (50 mg) and unevenly fractionated radiotherapy
Trial: 6150716
Drug: bezafibrate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (3 X 200 mg/die)
Trial: 6150716
Drug: somatostatin infusion
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: somatostatin infusion
Trial: 26705681
Drug: Weekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin (40 mg/m², 7 doses)
Trial: 26705681
Drug: Triweekly cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triweekly cisplatin (100 mg/m², 3 doses)
Trial: 16614779
Drug: 0.75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) t.i.d. intra‐anal using the cannula (Group A)
Trial: 16614779
Drug: 0.75 ml
RxNorm normalized name: ethanol 0.75 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 ml of 0.3 percent nitroglycerin ointment (2.25 mg nitroglycerin) perianally with the gloved finger (Group B)
Trial: 9542752
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (2 g daily) and d-alpha-tocopherol (1000 IU daily)
Trial: 8392820
Drug: Active medication
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active medication (0.3 mg atropine sulfate and 60 mg pseudoephedrine)
Trial: 8392820
Drug: Control (inert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (inert capsules)
Trial: 3556983
Drug: Intravenous cisapride
RxNorm normalized name: Cisapride
DrugBank: Cisapride (DB00604)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cisapride (8 mg)
Trial: 22815422
Drug: Oral ivabradine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ivabradine
Trial: 3884469
Drug: Oral metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metoprolol
Trial: 20207878
Drug: Mass azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mass azithromycin distributions (four biannual treatments)
Trial: 26286141
Drug: Umeclidinium/vilanterol (UMEC/VI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 mcg once daily
Trial: 26286141
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/SAL) 500/50 mcg twice daily
Trial: 23946220
Drug: Low-dose valacyclovir
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose valacyclovir (500 mg twice daily)
Trial: 23946220
Drug: High-dose valacyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose valacyclovir (1 g twice daily)
Trial: 21124260
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for predominant leg pain in DS patients
Trial: 21124260
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for predominant leg pain in SpS patients
Trial: 21124260
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment for equal pain groups in DS and SpS patients
Trial: 21124260
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment for predominant LBP patients
Trial: 15257469
Drug: 200 micro
RxNorm normalized name: Digoxin 200 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micro g of budesonide
Trial: 15257469
Drug: 800 micro
RxNorm normalized name: Fentanyl 800 microgram buccal film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 micro g of budesonide
Trial: 11397610
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional sympathetic blocks (n = 9)
Trial: 9407327
Drug: PUFA-enriched soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA-enriched soft oil capsules administered after each meal daily for 4 weeks
Trial: 9407327
Drug: PUFA-enriched soft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PUFA-enriched soft oil capsules
Trial: 8516523
Drug: Fentanyl (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (4 micrograms/kg) and saline (2 ml)
Trial: 8516523
Drug: Lidocaine (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1.5 mg/kg) and fentanyl (4 micrograms/kg)
Trial: 31702673
Drug: HT048 (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT048 (1000 mg)
Trial: 31702673
Drug: HT077 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT077 (400 mg)
Trial: 22103814
Drug: Peginterferon/ribavirin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peginterferon/ribavirin therapy
Trial: 11887809
Drug: 2-L exchange
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L exchange
Trial: 11887809
Drug: 2.5-L exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5-L exchange
Trial: 11887809
Drug: 3-L exchange
RxNorm normalized name: 3-(L-MENTHOXY)-2-METHYLPROPANE-1,2-DIOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-L exchange
Trial: 11887809
Drug: 2-L exchange
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L exchange (overnight)
Trial: 11887809
Drug: 2-L, 2.5-L,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L, 2.5-L, and 3-L exchanges
Trial: 7873457
Drug: formestane (Lentaron)
RxNorm normalized name: formestane
DrugBank: Formestane (DB08905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: formestane (Lentaron) 250 mg every 2 weeks by intramuscular injection
Trial: 7873457
Drug: tamoxifen 30
RxNorm normalized name: tamoxifen 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamoxifen 30 mg/day orally
Trial: 22204063
Drug: Meloxicam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meloxicam (0.1 mg/kg i.m.)
Trial: 18502208
Drug: 0.625 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg/d of conjugated equine estrogens
Trial: 18502208
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogens/d plus 2.5 mg medroxyprogesterone acetate/d)
Trial: 16979494
Drug: Experimental antiplaque
RxNorm normalized name: cetylpyridinium
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental antiplaque fluoridated formulation
Trial: 14609886
Drug: Sibutramine hydrochloride,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine hydrochloride, 15 mg/d
Trial: 11206010
Drug: High-dose continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose continuous tamoxifen (200 mg day(-1)), carboplatin (300 mg m(-2) for 3 cycles), and radiotherapy
Trial: 11206010
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (tamoxifen, carboplatin, and radiotherapy)
Trial: 1445483
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral contraceptive (30 micrograms ethinyl estradiol + 150 micrograms desogestrel)
Trial: 29377866
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group D)
Trial: 29377866
Drug: Intramuscular dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intramuscular dexamethasone 0.1 mg/kg (maximum 4 mg) with ropivacaine 0.5% (group M)
Trial: 29377866
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% and intramuscular saline (group R)
Trial: 26759167
Drug: Cognitive Remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Remediation Therapy (CRT) with Treatment as Usual (TAU)
Trial: 22007690
Drug: Varenicline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1.0 mg twice daily for 12 weeks with dose titration in the first week
Trial: 22007690
Drug: Varenicline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline 1.0 mg twice daily for 12 weeks
Trial: 11464257
Drug: Candesartan cilexetil
RxNorm normalized name: Candesartan Cilexetil
DrugBank: Candesartan cilexetil (DB00796)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Candesartan cilexetil 32 mg once daily
Trial: 9681128
Drug: Lenograstim (Granocyte)
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim (Granocyte) therapy
Trial: 970597
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg atropine i.v. in normothermia
Trial: 970597
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg atropine i.v. in hypothermia
Trial: 30642386
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose AmBisome therapy
Trial: 26063890
Drug: LET (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LET (2.5 mg/daily)
Trial: 26063890
Drug: LET-CYC (LET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LET-CYC (LET plus oral cyclophosphamide 50mg/daily)
Trial: 23583001
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no planned reminiscence treatment
Trial: 21558577
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg caffeine (6CAF)
Trial: 21558577
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg caffeine (2CAF)
Trial: 2135223
Drug: Telenzepine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telenzepine (5 mg, single oral dose)
Trial: 30844672
Drug: Self-affirmation intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-affirmation intervention prior to informing about chemotherapy-related cognitive problems
Trial: 30844672
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about chemotherapy-related cognitive problems
Trial: 25816807
Drug: everolimus (trough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL) with reduced cyclosporine
Trial: 25816807
Drug: everolimus (trough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: everolimus (trough concentration 3‐8 ng/mL or 6‐12 ng/mL)
Trial: 19392811
Drug: Massed group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massed group CBT (daily 4‐h sessions in week 1, two 2‐h sessions in week 2 and one 2‐h session in week 3)
Trial: 19392811
Drug: Traditional spaced
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional spaced weekly group CBT (13 consecutive, weekly 2‐h sessions)
Trial: 17217576
Drug: Sucrose supplements
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose supplements (4 x 250 ml per day, providing 1800 kJ per day)
Trial: 17217576
Drug: Sweetener supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweetener supplements (4 x 250 ml per day, providing 67 kJ per day)
Trial: 17217576
Drug: Sucrose supplements
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose supplements
Trial: 17217576
Drug: Sweetener supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sweetener supplements
Trial: 9669472
Drug: Nimodipine 90
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine 90 mg daily for 12 weeks
Trial: 24168756
Drug: Fluticasone (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone (alone or in combination with salmeterol)
Trial: 19800262
Drug: Intra-articular glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular glucocorticoid injections
Trial: 18241753
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (CPAD-IC)
Trial: 8881869
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion (0.5, 1, 2, 5 pmol.kg‐1.min‐1)
Trial: 8881869
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide infusion (5 pmol.kg‐1.min‐1)
Trial: 6781657
Drug: Inhaled verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled verapamil (estimated dose 3 mg)
Trial: 6781657
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate (estimated dose 12 mg)
Trial: 25873132
Drug: Pasireotide (long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide (long-acting release, 60 mg injection)
Trial: 23347140
Drug: Enoxaparin with
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin with vitamin K antagonist (VKA)
Trial: 21414740
Drug: FOLFOX4 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 regimen (oxaliplatin 85 mg/m(2) as a 2‐h infusion on day 1, leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Trial: 21414740
Drug: LV5Fu2 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LV5Fu2 regimen (leucovorin 200 mg/m(2)/d, 5‐fluorouracil 400 mg/m(2)/d bolus and 600 mg/m(2)/d infusion for 2 consecutive days every 2 weeks)
Trial: 19707146
Drug: Ultrasonographic measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonographic measurement of antral area 2 h after ingestion of 200 ml of nonclear liquids
Trial: 17689023
Drug: Capecitabine monotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks, followed by capecitabine (650-1,000 mg/m2 orally twice daily 5 days/week) combined with radiotherapy for 5 weeks.
Trial: 15279529
Drug: 2 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sessions of motivational enhancement therapy (MET)
Trial: 15279529
Drug: 9 sessions
RxNorm normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 sessions of multicomponent therapy (including MET, cognitive-behavioral therapy, and case management)
Trial: 11568588
Drug: Glutathione (GSH)
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (GSH) treatment, 600 mg in 4 mL saline per day, administered via nasal aerosol in five 2-minute sessions every 3 or 4 waking hours for 2 weeks.
Trial: 11568588
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 mL saline per day), administered via nasal aerosol in the same manner as GSH treatment.
Trial: 9272770
Drug: Low-carbohydrate diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate diet (L-CHO)
Trial: 1279497
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg flutamide for three months
Trial: 1279497
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg flutamide for three months
Trial: 1279497
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses (500 mg and 750 mg)
Trial: 22696517
Drug: Conservative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative therapy (pharmacological)
Trial: 20386884
Drug: Oxycodone 20
RxNorm normalized name: oxycodone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 20 mg + 0.0001 mg NTX
Trial: 20386884
Drug: Oxycodone 20
RxNorm normalized name: oxycodone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 20 mg + 0.001 mg NTX
Trial: 20386884
Drug: Oxycodone 40
RxNorm normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 40 mg + 0.0001 mg NTX
Trial: 20386884
Drug: Oxycodone 40
RxNorm normalized name: ibuprofen-oxycodone 400 mg-5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 40 mg + 0.001 mg NTX
Trial: 18541560
Drug: Micronutrient-fortified seasoning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient-fortified seasoning powder (5 mg Fe, 5 mg Zn, 50 mug I, 270 mug vitamin A per serving) consumed with school lunch 5 days/week
Trial: 7483181
Drug: Medical strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical strategies with low to moderate doses of medication titrated over 12 weeks
Trial: 27229348
Drug: Agomelatine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Agomelatine 50 mg/day